SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
She reported her experience to Novo Nordisk and to the FDA
In both cases, I am finding the optimal pharmacologic dose for ongoing treatment
Community Support : Weight loss can be a challenging journey, and having a supportive community can make a significant difference
Because it is fun, you are more likely to repeat it
The pharmaceutical company Novo Nordisk told CNN in July that GLP-1 agonists have been studied in detail and in use for several years
:max_bytes(150000):strip_icc()/tamiflu-side-effects-2633814_final-01-87f96643c6b841f2b9cefbe8003e9162.png)
